Genomic Health, Inc. (NASDAQ:GHDX) – Equities research analysts at William Blair issued their Q1 2018 earnings estimates for shares of Genomic Health in a note issued to investors on Monday. William Blair analyst A. Murphy expects that the medical research company will earn $0.07 per share for the quarter. William Blair also issued estimates for Genomic Health’s Q2 2018 earnings at $0.02 EPS, Q3 2018 earnings at $0.07 EPS and Q4 2018 earnings at $0.13 EPS.

Several other research firms also recently commented on GHDX. Jefferies Group LLC reissued a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research note on Friday, October 20th. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. Cowen and Company reissued a “hold” rating and set a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and set a $35.00 price target on shares of Genomic Health in a research note on Wednesday, September 27th. Finally, BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $32.67.

ILLEGAL ACTIVITY NOTICE: This story was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/16/analysts-issue-forecasts-for-genomic-health-inc-s-q1-2018-earnings-ghdx.html.

Genomic Health (NASDAQ:GHDX) traded up $0.23 during mid-day trading on Tuesday, hitting $28.61. 149,600 shares of the company’s stock traded hands, compared to its average volume of 119,058. Genomic Health has a 52-week low of $26.37 and a 52-week high of $34.02.

Large investors have recently added to or reduced their stakes in the stock. Eagle Asset Management Inc. boosted its holdings in Genomic Health by 18.4% in the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after acquiring an additional 58,920 shares in the last quarter. American International Group Inc. boosted its holdings in Genomic Health by 7.1% in the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock valued at $362,000 after acquiring an additional 765 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Genomic Health by 10.9% in the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock valued at $26,473,000 after acquiring an additional 80,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Genomic Health by 26.1% in the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock valued at $12,070,000 after acquiring an additional 76,758 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Genomic Health by 190.7% in the second quarter. GSA Capital Partners LLP now owns 43,900 shares of the medical research company’s stock valued at $1,429,000 after acquiring an additional 28,800 shares in the last quarter. Institutional investors and hedge funds own 89.13% of the company’s stock.

In related news, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $31.00, for a total transaction of $155,000.00. The disclosure for this sale can be found here. Insiders sold 21,379 shares of company stock worth $676,131 in the last 90 days. Company insiders own 46.20% of the company’s stock.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.